JASCAYD DIN 02572362
Status: Approved
Holder: BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Health Canada record
| Active ingredient(s) | NERANDOMILAST 18 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION RECOMMENDED |
|---|
| Class | Human |
|---|
| ATC | L04AA61 NERANDOMILAST |
|---|
| Original market date | |
|---|
| Current status date | 08-Oct-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NERANDOMILAST
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02572354 | JASCAYD | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet | NERANDOMILAST 9 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 38430 | 2026-10-08 | New Drug Submission (NDS) | |
Request a quote for JASCAYD
How to read a Canadian DIN record